Pushing Forward: Venture Capitalist Priorities To Accelerate European Biotech
Executive Summary
Sharing his thoughts on the European funding landscape, the importance of software, and sustainable investments, INKEF Capital’s Thijs Cohen Tervaert talks to In Vivo about his investment priorities.
You may also be interested in...
Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR
When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.
Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR
When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.
The Journey Has Just Begun For LAG-3 Therapeutics
Clinical stage innovator Immutep talks to In Vivo about the potential for LAG-3 antibodies in cancer and autoimmune diseases.